Related Experiment Video
Updated: Aug 16, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients
María Belén Montú1, Walter Oleschko Arruda, Marcelo de Souza R de Oliveira
1Instituto de Neurologia de Curitiba, Curitiba PR, Brasil. belenmontu@hotmail.com
Abstract:
Mitoxantrone hydrochloride (Novantrone) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6 +/- 10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5 +/- 6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg).
Related Concept Videos
Multiple Sclerosis l: Introduction
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Atherosclerosis III: Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...